Literature DB >> 24982044

Clinical reasoning: progressive visuospatial problems in a 71-year-old man.

Mkael Symmonds1, Wilhelm Küker2, Ursula G Schulz2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24982044      PMCID： PMC4114177          DOI： 10.1212/WNL.0000000000000548

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  9 in total

1.  Reversible posterior leucoencephalopathy during oral treatment with methotrexate.

Authors:  Dimitri Renard; Rene Westhovens; Erik Vandenbussche; Rik Vandenberghe
Journal:  J Neurol       Date:  2004-02       Impact factor: 4.849

2.  Posterior reversible encephalopathy syndrome and oral methotrexate.

Authors:  Caroline Hart; Michael O Kinney; Mark O McCarron
Journal:  Clin Neurol Neurosurg       Date:  2012-01-04       Impact factor: 1.876

Review 3.  Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

4.  Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate.

Authors:  S Raghavendra; M D Nair; T Chemmanam; T Krishnamoorthy; V V Radhakrishnan; A Kuruvilla
Journal:  Eur J Neurol       Date:  2007-03       Impact factor: 6.089

Review 5.  Biochemical and clinical aspects of methotrexate neurotoxicity.

Authors:  Sandra Vezmar; Achim Becker; Udo Bode; Ulrich Jaehde
Journal:  Chemotherapy       Date:  2003-05       Impact factor: 2.544

6.  Regression of chronic posterior leukoencephalopathy after stop of methotrexate treatment.

Authors:  Gabriella Marcon; Anna Rita Giovagnoli; Paola Mangiapane; Alessandra Erbetta; Fabrizio Tagliavini; Floriano Girotti
Journal:  Neurol Sci       Date:  2009-07-21       Impact factor: 3.307

7.  Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy.

Authors:  W H Sommer; V Ganiere; D Gachoud; A Keta; A Abou-Hajar; J Dudler; D Aujesky
Journal:  Scand J Rheumatol       Date:  2008 Jul-Aug       Impact factor: 3.641

8.  Leukoencephalopathy due to oral methotrexate.

Authors:  I González-Suárez; M J Aguilar-Amat; M Trigueros; A M Borobia; A Cruz; J Arpa
Journal:  Cerebellum       Date:  2014-02       Impact factor: 3.847

9.  Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.

Authors:  Enrico C Lallana; Camilo E Fadul
Journal:  Curr Neuropharmacol       Date:  2011-09       Impact factor: 7.363
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.